Latest Tau protein Stories
A new study shows that a new drug, called epothilone D (EpoD) is preventing neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD).
A study published this week in the Journal of Neuroscience shows that the compound epothilone D (EpoD) is effective in preventing further neurological damage and improving cognitive performance in a mouse model of Alzheimer's disease (AD).
A compound that previously progressed to Phase II clinical trials for cancer treatment slows neurological damage and improves brain function in an animal model of Alzheimer's disease.
Slowing or preventing the development of Alzheimer’s disease, a fatal brain condition expected to hit one in 85 people globally by 2050, may be as simple as ensuring a brain protein’s sugar levels are maintained.
One of the most distinctive signs of the development of Alzheimer's disease is a change in the behavior of a protein that neuroscientists call tau. In normal brains, tau is present in individual units essential to neuron health.
For decades, researchers have debated whether Alzheimer's disease starts independently in vulnerable brain regions at different times, or if it begins in one region and then spreads to neuroanatomically connected areas.
Neurofibrillary tangles – odd, twisted clumps of protein found within nerve cells – are a pathological hallmark of Alzheimer's disease.
Scientists from the National Institutes of Health in the United States have made an important discovery that should forever change the scope and direction of Alzheimer's research.
HOBOKEN, NJ, July 25, 2011 /PRNewswire/ - Anavex Life Sciences Corp.